Raphael Pharmaceutical Inc.
RAPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RAPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RAPH
Raphael Pharmaceutical Inc. (RAPH) is a development-stage biopharmaceutical company focused on advancing product candidates through FDA and EMA regulatory pathways, with no current revenue and a negative shareholders' equity as of 2026-06-30.
Key risk: Liquidity crisis
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$28.2M
Cash Runway
—
Lead Asset
covid-19 product candidate (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Raphael Pharmaceutical Inc..
Raphael Pharmaceutical Inc. (RAPH) is a development-stage biopharmaceutical company focused on advancing product candidates through FDA and EMA regulatory pathways, with no current revenue and a negative shareholders' equity as of 2026-06-30.
- Raphael Pharmaceutical is a development-stage company with no approved products and no revenue, as indicated by its reliance on regulatory pathways for FDA and EMA approvals [sec_mda · as of 2025-08-13].
- As of 2026-06-30, the company reported cash & equivalents of $0.0M, net income of -$0.2M, and shareholders' equity of -$1.4M [sec].
- The company's forward-looking statements highlight risks related to obtaining regulatory approvals, commercial launch, and the cost of advancing product candidates [sec_mda · as of 2025-08-13].
- Raphael Pharmaceutical's financial condition is characterized by a negative equity position and minimal cash, suggesting significant funding needs for ongoing operations [sec].
What works
- The company is actively pursuing regulatory pathways with the FDA and EMA, which could lead to product approvals if successful [sec_mda · as of 2025-08-13].
- Raphael Pharmaceutical has a pipeline of product candidates for multiple indications, providing potential for future revenue streams [sec_mda · as of 2025-08-13].
What to weigh
- The company has no approved products or revenue, and its cash position of $0.0M as of 2026-06-30 indicates a critical lack of liquidity to fund operations [sec].
- Shareholders' equity is negative at -$1.4M as of 2026-06-30, reflecting accumulated losses and financial distress [sec].
- The company faces significant regulatory and commercial risks, including the cost and uncertainty of obtaining FDA and EMA approvals [sec_mda · as of 2025-08-13].
From the filings
Quoted directly from source documents.
The company's forward-looking statements include risks related to regulatory approvals and commercial launch.
“obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to our product candidates;”
SEC MD&A · August 13, 2025
The company is a development-stage entity with no current revenue.
“the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline;”
SEC MD&A · August 13, 2025
Risks & what to watch (2)›
Key risks
- Liquidity crisis — Cash of $0.0M as of 2026-06-30 indicates inability to fund operations without new financing [sec].
- No revenue stream — No approved products or revenue, relying solely on future product candidates [sec_mda · as of 2025-08-13].
What to watch
- Any new financing or capital raise to address the $0.0M cash position [sec].
- Updates on regulatory submissions or interactions with FDA/EMA for product candidates [sec_mda · as of 2025-08-13].
- Clinical trial progress or pipeline advancement for any indications [sec_mda · as of 2025-08-13].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Raphael Pharmaceutical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Raphael Pharmaceutical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF $0 · Net income -$223K
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Raphael Pharmaceutical Inc.?
Raphael Pharmaceutical Inc. (RAPH) is a development-stage biopharmaceutical company focused on advancing product candidates through FDA and EMA regulatory pathways, with no current revenue and a negative shareholders' equity as of 2026-06-30.
What is Raphael Pharmaceutical Inc.'s lead drug candidate?
Raphael Pharmaceutical Inc.'s most advanced tracked candidate is covid-19 product candidate (Preclinical) for Hyperinflammatory syndrome related to COVID-19.
Who is the CEO of Raphael Pharmaceutical Inc.?
Mr. Shlomo Pilo is the chief executive officer of Raphael Pharmaceutical Inc. (RAPH).
Where is Raphael Pharmaceutical Inc. headquartered?
Raphael Pharmaceutical Inc. (RAPH) is headquartered in Jaffa, Israel.
What therapeutic areas does Raphael Pharmaceutical Inc. focus on?
Raphael Pharmaceutical Inc. develops therapies across Immunology, Infectious Disease, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.